U-GNTA

Q:GNTA - GENENTA SCIENCE SPA SPON ADS EACH REP 1 ORD SHS - http://www.genta.com

21:08:54 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
GNTA - Q	0.1	2.74	·	5.15	0.1	3.20	-0.02	-0.6	3.6	10	25	3.17 3.3735 3.0016	6.81 2.20	16:00:01	May 06	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 25

More trades...

Time ET	Ex	Price	Change	Volume
16:00:01	Q	3.20	-0.02	1
15:59:55	Q	3.20	-0.02	120
15:59:48	Q	3.20	-0.02	223
15:59:17	Q	3.3735	0.1535	100
13:52:49	Q	3.2001	-0.0199	162
12:52:35	Q	3.17	-0.05	3
11:11:15	Q	3.23	0.01	4
10:54:45	Q	3.23	0.01	6
10:51:38	Q	3.30	0.08	3
10:47:55	Q	3.04	-0.18	50

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-05-06 06:25	U:GNTA	News Release200	Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
2024-02-08 05:00	U:GNTA	News Release200	Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
2023-09-06 07:00	U:GNTA	News Release200	Genenta to Present at Upcoming Scientific and Investor Conferences
2023-07-28 03:00	U:GNTA	News Release200	Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
2023-06-29 07:00	U:GNTA	News Release200	The European Commission Grants Orphan Drug Designation to Temferon ¢ „ ¢ for Treatment of Glioma

Date ET

Symbol

Type

Headline

2024-05-06 06:25

U:GNTA

News Release

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

2024-02-08 05:00

U:GNTA

News Release

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors